USANA amends credit agreement, lowers EBITDA covenant floor and expands asset sale basket
USANA Health Sciences amended its $75 million revolving credit facility on September 30, 2026, with Bank of America as administrative agent, and the facility matures June 27, 2030. The amendment sets a minimum trailing four-quarter Consolidated EBITDA covenant of $100 million starting with the quarter ending October 3, 2026, which drops to $70 million when revolving exposure is $50 million or less, and raises the annual general asset sale basket from $500,000 to $2.5 million.
Key points
- Revolving credit facility of $75 million, maturing June 27, 2030, with an option to increase by more than $200 million on request
- Minimum Consolidated EBITDA covenant of $100 million, reduced to $70 million when lender revolving exposure is $50 million or less
- Annual general asset sale basket raised from $500,000 to $2.5 million
- New permission for USANA Australia Pty, Ltd to sell Sydney, Australia real property; sale and leaseback transactions remain generally prohibited
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.